Test Price
2,800 AED✅ Home Collection Available
CYP1A2 Gene Cytochrome P450 Deficiency Genetic Test in UAE
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015‑accredited NGS processing. Every variant in the CYP1A2 gene is sequenced at >100× depth, detecting all clinically relevant single‑nucleotide variants, insertions, deletions, and copy‑number alterations.
Premium Logistics: VIP mobile phlebotomy & temperature‑controlled cold‑chain home collection across all Emirates (8 AM – 11 PM). Booking via WhatsApp at +971 54 548 8731 with same‑day slots frequently available.
Clinical Guidance: Complimentary telephonic post‑test interpretation with a DHA‑licensed consultant medical geneticist to translate pharmacogenomic findings into personalised therapy adjustments.
Insurance Support: Instant direct‑billing eligibility check via WhatsApp at +971 54 548 8731; share your Emirates ID or policy card for confirmation within minutes.
Test Overview & Methodology
The CYP1A2 Gene Cytochrome P450 Deficiency Genetic Test detects clinically actionable variants in the CYP1A2 gene that impair metabolism of caffeine, clozapine, theophylline, and numerous other substrates. This Next‑Generation Sequencing assay covers the entire coding region and exon‑intron boundaries, providing a comprehensive pharmacogenomic risk profile to guide personalised medication dosing and reduce adverse drug reactions. The test is performed under strict ISO 9001:2015 quality management and follows DHA‑approved clinical protocols.
| Feature | Our Test (NGS Full‑Gene) | Closest Alternative (SNP Panel) |
|---|---|---|
| Methodology | NGS (Next‑Generation Sequencing) | Targeted genotyping (TaqMan®) |
| Variant Detection | All SNVs, indels, CNVs – novel & known | Pre‑defined common polymorphisms only |
| Sensitivity | >99.9% (clinical performance validated) | ~85% – misses rare pathogenic mutations |
| Turnaround Time | 3–4 weeks | 3–5 business days |
| Clinical Scope | Comprehensive CYP1A2 deficiency assessment | Limited to four common alleles |
Physician Insight & Safety Protocols
“The CYP1A2 pharmacogenomic profile offers a detailed window into hepatic metabolic capacity, but genetic findings must always be integrated with the complete clinical picture – including concurrent medications, hepatic function, and individual patient history. I emphasise that this test is a decision‑support tool, never a substitute for ongoing clinician‑patient dialogue. Even a result classified as ‘normal’ requires full contextual interpretation by a qualified genetics specialist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Advisory
Do not discontinue, reduce, or modify any prescribed medication without explicit instruction from your attending physician, even if you receive a CYP1A2 deficiency result. Genetic findings indicate metabolic capacity but cannot replace clinical judgement.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inability to provide informed consent; minors without parental/legal guardian consent; patients with uncontrolled active bleeding that precludes safe venipuncture.
- Pre‑Test Requirement: A pre‑test genetic counselling session with pedigree chart documentation is mandatory to contextualise family risk of cytochrome P450 deficiency.
- Emergency Red Flags: If you experience sudden onset of severe adverse drug effects – such as profound sedation, respiratory depression, severe hypotension, or anaphylaxis – call 998 (UAE ambulance) immediately. Do not wait for the test result.
Patient FAQ & Clinical Guidance
1. How accurate is the CYP1A2 NGS test for determining my drug metabolism capacity?
This test delivers >99.9% diagnostic sensitivity by sequencing the entire CYP1A2 gene, detecting all pathogenic variants that may affect metabolism. The comprehensive NGS method covers coding regions and splice sites, ensuring that rare and novel mutations are not missed, unlike limited SNP panels. All results are validated against public pharmacogenomic databases and correlated with clinical outcome literature.
2. Why does the test take 3 to 4 weeks – can it be expedited?
Full NGS library preparation, sequencing at deep coverage, bioinformatic variant calling, and manual clinical review require 21 days to guarantee ISO‑certified quality. Every sample undergoes a two‑step orthogonal confirmation of pathogenic variants. The additional time allows for Sanger validation of mutations and comprehensive report drafting by a DHA‑licensed consultant medical geneticist, ensuring every finding meets DHA reporting standards. No expedited service is offered because quality cannot be compromised.
3. Can home blood collection be arranged across the UAE for this test?
Yes, our VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection service covers all Emirates from 8 AM to 11 PM. A trained DHA‑licensed phlebotomist arrives at your preferred location with a validated CYP1A2‑specific collection kit (whole blood or dry blood spot on FTA card). Samples are immediately placed in a temperature‑monitored container and transported directly to the genomic laboratory. Booking is available via WhatsApp at +971 54 548 8731, and same‑day slots are often possible.
4. What information will my test report contain?
Your report includes all detected variants in the CYP1A2 gene, their clinical significance classifications per ACMG/AMP guidelines, predicted metabolic phenotype (e.g., poor, intermediate, normal, or ultrarapid metaboliser), and medication‑specific dosing recommendations derived from peer‑reviewed pharmacogenomic evidence. A post‑test telephonic consultation with our consultant medical geneticist is included to ensure you fully understand your results and their implications for your treatment plan.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
This test is conducted in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and processed solely for diagnostic and therapeutic purposes as per the patient’s written informed consent. Clinical safety and patient consent procedures adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Our genomic laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and operates under the regulatory oversight of the Dubai Health Authority (DHA). The NGS methodology is validated and aligned with international quality standards for pharmacogenomic testing.
Clinical & Logistical Metadata
| Test Name | CYP1A2 Gene Cytochrome P450 Deficiency Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks (21–28 business days) |
| Sample Type / Matrix | Whole Blood (peripheral) or Dry Blood Spot on FTA card; DNA extracted for NGS analysis |
| Methodology Used | Next‑Generation Sequencing (NGS) – full gene sequencing including coding regions and exon‑intron boundaries |
| ICD‑10‑CM Code | Z13.71, Z13.79, Z15.89 |
| LOINC Code | 69900-6 (CYP1A2 gene full gene analysis) |
| DHA Facility License & Laboratory Address | License No. 1143 · Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE · DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians